Frontiers in pharmacology
January 1, 2018
Joaquín González, José P Prieto, Paola Rodríguez et al.
31 citations
Ibogaine, a psychedelic alkaloid with anti-addictive properties, acutely increases wakefulness and suppresses REM sleep in rats. In a study with polysomnographic recordings over six hours, rats given ibogaine (20 or 40 mg/kg) spent more time awake and less time in slow wave sleep and REM sleep compared to controls. REM sleep latency increased with the higher dose. The wake-promoting and slow wave sleep effects occurred in the first two hours, while REM suppression lasted throughout the recording. Lower doses increased locomotion; higher doses caused tremor and flat body posture. Head shake response, linked to 5HT2A receptor activation, was unchanged. The findings suggest ibogaine produces a waking state with prolonged REM suppression and a dose-dependent motor profile.
ACS pharmacology & translational science
April 9, 2021
Joaquín González, Matías Cavelli, Santiago Castro-Zaballa et al.
26 citations
Ibogaine, a psychedelic alkaloid with anti-addictive potential, produces vivid, dream-like experiences while awake. Analyzing intracranial electroencephalograms in rats, ibogaine-induced wakefulness showed gamma oscillations with greater power than control levels but reduced coherence and complexity. This gamma activity profile resembled that of natural REM sleep, providing biological evidence linking the psychedelic state to REM sleep and advancing understanding of ibogaine's oneirogenic effects.
International journal of molecular sciences
January 5, 2024
Sofía Villalba, Bruno González, Stephanie Junge et al.
9 citations
Noribogaine, the primary metabolite of ibogaine, produces sexually dimorphic effects in mice, with some responses depending on the 5-HT2A receptor. A single 40 mg/kg dose reduced locomotion in male but not female wild-type mice. Gene expression of immediate early genes and glutamate receptors differed by sex and genotype. 5-HT2A receptor mRNA increased in the medial prefrontal cortex after noribogaine at 10 mg/kg in males and 40 mg/kg in females. Electrophysiology showed that 40 mg/kg reduced NMDA-mediated postsynaptic current density in layer V pyramidal neurons of the medial prefrontal cortex only in male wild-type mice, an effect absent in 5-HT2A receptor knockout males and all females. The genetic removal of the 5-HT2A receptor blunted noribogaine's effects on NMDA synaptic transmission.
bioRxiv (Cold Spring Harbor Laboratory)
June 29, 2020
Joaquín González, Matías Cavelli, Santiago Castro‐zaballa et al.
5 citations
preprint
Ibogaine, a psychedelic alkaloid with anti-addictive properties, produces a waking state that shares brain-wave traits with REM sleep. In rats, ibogaine increased gamma oscillation power in the brain but made those oscillations less coherent and less complex than normal waking levels. This pattern mirrors REM sleep features within the gamma frequency band, providing biological evidence for the long-standing hypothesis that ibogaine induces a dream-like state while awake—a phenomenon called oneirogenesis. The findings offer an empirical basis for understanding how ibogaine's unique subjective effects may contribute to its anti-addictive potential.
Behavioural brain research
January 5, 2025
Santiago Castro-Zaballa, Joaquín González, Matías Cavelli et al.
4 citations
In cats, high-frequency oscillations (HFO, >100 Hz) in the brain's electrical activity are linked to breathing during wakefulness but not during sleep. A sub-anesthetic dose of ketamine increases the power of these HFO, and they remain tied to the inhalation phase of respiration. The enhanced HFO appear to originate in the olfactory bulb and travel to the prefrontal cortex. Blocking the nostrils reduces the ketamine-enhanced HFO in both regions. Auditory stimulation does not affect these oscillations. The findings suggest that ketamine's enhancement of respiration-coupled HFO may disrupt cortical information processing, potentially contributing to its neuropsychiatric effects.
Psychopharmacology
July 1, 2024
Juan Pedro Castro-Nin, Diego Serantes, Paola Rodríguez et al.
4 citations
Noribogaine, the main metabolite of the psychedelic ibogaine, promotes wakefulness while reducing slow-wave sleep and blocking REM sleep in rats, according to polysomnographic recordings. This pattern of sleep/wake alterations is similar to that previously reported for ibogaine itself. The findings provide new evidence on how iboga alkaloids act in the brain, suggesting that noribogaine contributes to the sleep-suppressing effects observed after ibogaine administration.
bioRxiv (Cold Spring Harbor Laboratory)
July 28, 2023
Juan Pedro Castro‐nin, Diego Serantes, Paola Rodrı́guez et al.
1 citation
preprint
Noribogaine, the main metabolite of the psychedelic ibogaine, promotes wakefulness and reduces slow-wave sleep while completely blocking REM sleep in rats. These sleep-wake alterations mirror those caused by ibogaine itself, suggesting that noribogaine is responsible for the sleep-suppressing effects previously attributed to ibogaine. The findings point to serotonin reuptake inhibition as a likely mechanism underlying the wake-promoting and REM sleep-suppressing actions of both compounds.